Hematology

Azacitidine (Onureg) was approved by the FDA in September 2020 as a maintenance therapy for acute myeloid leukemia.

Results from the LOTIS-2 and LOTIS-3 trials show durable responses and a manageable toxicity profile among patients with both diffuse large B-cell lymphoma and mantle cell lymphoma treated with loncastuximab tesirine-lpyl (Zynlonta).

The demand for drug treatments in Europe and North American has increased in recent years, as awareness of the bleeding disorder rises.

The FDA also approved dabigatran etexilate oral pellets for the prevention of recurrent clots in patients aged 3 months to less than 12 years of age who have completed treatment for their first venous thromboembolism.

Pharmacists can educate patients about a pair of new treatment options for multiple myeloma approved by the FDA in March 2021.

The findings led to the FDA accepting the supplemental Biologics License Application and Priority Review designation for treatment, according to a Gilead press release.

Avapritinib is approved for adult patients with advanced systemic mastocytosis, including individuals with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

Updated research offers an additional 2 years of follow-up data and statistics on treatment with a combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia.

The addition of daratumumab to lenalidomide and dexamethasone resulted in a significant benefit to overall survival in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant and were treated to progression, according to the results of the phase 3 MAIA study.

Results from part A of a phase 3 trial showed sutimlimab caused patients to experience a rapid and sustained inhibition of C1-activated hemolysis in patients with cold agglutinin disease.

Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors.

Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Selinexor in combination with bortezomib and dexamethasone is used for adult patients with multiple myeloma who have received at least 1 prior therapy.

Ssatuximab (Sarclisa, Sanofi) is used in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Melphalan flufenamide (Pepaxto; melflufen) is approved for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.

Tivozanib was the first therapy approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma following 2 or more prior systemic therapies.

The researchers obtained genomic data from more than 2000 pediatric patients with leukemia to identify associated gene variants.

Although prolonged COVID-19 infections are rare, even in children or young adults with compromised immunity, it could have public health implications.

The AHA released a report to provide guidance about CVST, TTS, and VITT after receiving the COVID-19 vaccine.

Fatigue-inducing anemias caused by chronic diseases and inflammation may be treatable with a combination of inexpensive oral medications, according to a study published in Nature Communications.

Use of tranexamic acid is not associated with complications such as deep vein blood clots, heart attacks, seizures, or strokes or mini strokes when used in high-risk patients, according to a study published in Anesthesiology.

An interim analysis from the phase 3 ALPINE trial comparing zanubrutinib against ibrutinib demonstrated positive results in the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.